BRIEF—Label expansion for Repatha in Japan

Amgen Astellas BioPharma (AABP), a joint venture between US biotech Amgen and Japanese drug major Astellas Pharma, have expanded the label in Japan for Repatha (evolocumab).

The supplemental indication is for treating hypercholesterolemia patients who are not suitable for statin therapy.

The approval will make it possible for Repatha to be used alone in hypercholesterolemia patients for whom statin therapy is not suitable, due to a history of side effects or a contraindication.